BPR277

Phase 1Small molecule

Novartis

BPR277 is one of 7 small molecule programs targeting Netherton syndrome. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Netherton SyndromeActive, not recruiting

Netherton SyndromePhase 1

Active, not recruiting

Competition

Competitive Landscape

15 competitors in Netherton Syndrome

#DrugCompanyPhaseTrials

Elidel

BBausch Health Americas, Inc.

Approved

—2

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Phase 2

1 3

Humira

CCelltrion

Phase 2

1 4

Spevigo

Boehringer Ingelheim

Phase 2

1 5

Ds-2325a

Daiichi Sankyo

Phase 2

1 6

Stool Collect

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 7

BPR277

Novartis

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Netherton syndrome1 trial

A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome

Completed· Novartis logo

Novartis·Phase 1·NCT01428297·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BPR277. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BPR277 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BPR277. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Novartis

BPR277

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Netherton syndrome1 trial

References

Drug Info

Quick Facts

Related News